Open AccessTX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
Author(s) -
Ginger D. Constantine,
James A. Simon,
Andrew M. Kaunitz,
James H. Pickar,
Dennis A. Revicki,
Shelli Graham,
Brian Bernick,
Sebastián Mirkin
Publication year - 2020
Publication title -
menopause
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.086
H-Index - 103
eISSN - 1530-0374
pISSN - 1072-3714
DOI - 10.1097/gme.0000000000001602
Subject(s) - medicine , vasomotor , randomized controlled trial , physical therapy , intensive care medicine
The aim of the study was to evaluate the clinically meaningful effect of oral TX-001HR (17β-estradiol [E2]/progesterone [P4]) capsules on hot flushes severity (vasomotor symptoms [VMS] severity scale) using the patient-reported Clinical Global Impression (CGI).